Syndax Pharmaceuticals, Inc. ( NASDAQ: SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia October 24, 2025 2:30 PM EDT ...
The Raiju V3 Pro seems about as good as a third-party PS5 wireless controller can be, despite a few omissions. It lacks ...
Reimagining pharmacy benefits modular empowers health systems with technology-driven control, transparency, and improved patient care management.
AMCP Nexus 2025 will focus on drug pricing, access, and reimbursement, influenced by the Inflation Reduction Act and One Big ...
TipRanks on MSN
Syndax confirms FDA approves second indication for Revuforj
Pharmaceuticals announced that the U.S. Food and Drug Administration has approved Revuforj for the treatment of relapsed or ...
Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
Recursion Pharmaceuticals (RXRX) ended the recent trading session at $5.75, demonstrating a -5.89% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily ...
In a Phase II trial, 23 percent of patients achieved complete remission plus complete remission with partial hematologic recovery on Revuforj.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback